Geneseeq Technology Inc. and Zai Lab, Ltd. entered a new strategic collaboration in Shanghai, China to facilitate the R&D and commercialization of Zai Lab’s cancer drugs through business partnerships in clinical trial patient recruitment, central lab testing, companion diagnostics development and marketing activities. 

Marc Zhao, the co-founder and Chief Operating Officer of Geneseeq, said, “Geneseeq and Zai Lab hope to use this strategic collaboration as the cornerstone to combine resources of both companies to provide high-quality cancer diagnostics and treatment solutions. I look forward to further joint actions between the two parties to improve cancer patient outcomes and generate positive societal impact.”
 
William Liang, Chief Commercial Officer of Zai Lab and President of Greater China said, “In recent years, advances in genetic testing technology have boosted the continuous improvement of precision medicine and treatment programs. Zai Lab has three products listed in China with 10-15 more products expected to be approved. Many of them rely on biomarker testing. We hope to work with genetic testing partners to help patients achieve precise and personalized treatment. At the same time, we also look forward to working with these partners to improve the efficiency of drug research and development, shorten the development cycle, and accelerate product approvals.”